The Company is guiding to Q4 2023 revenue of $71 to $76 million, which includes core revenue of $33 to $35 million and InteliSwab(R) revenue of $38 to $41 million. As part of our ongoing focus on enterprise-wide operating efficiency, the Company is on track to exceed the $15 million of annualized cost savings announced in Q1 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OSUR:
